Indian Drugmaker To Produce 200 Million Doses, Says Russia's Sputnik V Developer
NDTV
The Russian Direct Investment Fund (RDIF), which backed the development of Sputnik V, said in a statement it had partnered with Stelis Biopharma "to produce and supply a minimum of 200 million doses of the Russian Sputnik V vaccine".
The developer of Russia's Sputnik V coronavirus vaccine said Friday it had signed a partnership with an India-based drugmaker for the production of 200 million doses of the two-dose jab. The Russian Direct Investment Fund (RDIF), which backed the development of Sputnik V, said in a statement it had partnered with Stelis Biopharma "to produce and supply a minimum of 200 million doses of the Russian Sputnik V vaccine". (Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)More Related News